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Abstract
We measured hair and plasma concentrations of isoniazid among sixteen children with
tuberculosis who underwent personal or video-assisted directly observed therapy and thus
had 100% adherence. This study therefore defined typical isoniazid exposure parameters
after two months of treatment among fully-adherent patients in both hair and plasma
(plasma area under the concentration-time curve, AUC, estimated using pharmacokinetic
data collected 0, 2, 4, and 6 hours after drug administration). We found that INH levels in
hair among highly-adherent individuals did not correlate well with plasma AUC or trough
concentrations, suggesting that each measure may provide incremental and complemen-
tary information regarding drug exposure in the context of TB treatment.
Background
Tuberculosis (TB) is the most common cause of morbidity and mortality from an infectious
agent globally [1]. Children with TB constitute 10% of the total global burden of TB with an
approximate 1 million cases occurring among children younger than 15 years [1]. Maintaining
adequate adherence to anti-TB drugs for a minimum of 6-months for active TB is essential
(but challenging in children, the group at highest risk of TB-related mortality) [2]. Further-
more, each of the drugs in the recommended standard anti-TB treatment (ATT) regimen -iso-
niazid (INH), rifampicin (RIF), ethambutol (EMB) and pyrazinamide (PZA)- has a specific
role in sterilizing both semi-dormant and actively multiplying mycobacterial bacilli, required
for successful TB treatment outcomes [3](3). Finally, for global TB control and to reach the tar-
get of zero deaths from TB [4], it is critical to optimize existing TB prophylaxis strategies,
including INH preventive therapy (IPT), specifically for children < 5years of age, who are at
high risk of developing TB after household or other closely-affiliated exposure to active TB
[1,2]. Maintaining adequate exposure to IPT is also a critical feature to its durable success.
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Optimal drug exposure to ATT and IPT ensure killing of Mycobacterium tuberculosis bacilli,
but best practices to measure drug exposure to anti-TB drugs remain elusive [5]. Treatment
adherence as measured by adherence questionnaires and pill counts can be subject to social
desirability and recall biases. Moreover, self-report or pill counts cannot capture actual drug
ingestion and drug exposure [6]. Drug exposure is often measured by single plasma drug lev-
els, but these levels represent only a small window of exposure and exhibit high rates of intra-
individual variability [7,8]. Furthermore, plasma drug measurement requires skilled phleboto-
mists, cold chain for storage and shipment, and sampling timed to dose, limiting the use of
this measure in routine clinical practice. Exposure measures from intensive pharmacokinetics
(PK) studies are even more difficult to perform in clinical practice. Dried blood spot (DBS)
analysis, using fingerprick sampling, is relatively simple, but this technology is still in the initial
stages of development for anti-TB drugs and requires validation; moreover, the stability of
some TB drugs (rifampin, isoniazid) in DBS is poor [9,10].
Hair assays of drugs have emerged as an alternate, noninvasive, innovative tool that can
capture drug exposure and adherence [11]). Drugs gets incorporated into hair over weeks to
months and concentrations in 1cm of hair represent approximately one month of drug expo-
sure [12]. Our group has developed expertise in the development of hair assays for antiretrovi-
rals (ARVs) and shown multiple uses for hair ARV concentrations in the setting of HIV
treatment and prevention [13–19]. Building on earlier work by Eisenhut et al [20], we have
previously shown that INH can be detected in the hair of children on ATT and that INH con-
centrations in hair are quantifiable over a dynamic range [21, 22]. Typical ranges of INH hair
concentrations in fully adherent pediatric patients have not yet been defined. In this study, we
provide initial data about typical values for INH hair levels and plasma area-under-the-curve
concentrations from intensive PK studies- as well as their correlation- in a cohort of HIV-
infected and uninfected children on ATT under directly observed therapy.
Methods
A prospective cohort study of children with TB was established at BJ Government Medical
College (BJGMC)—Sassoon General Hospital (SGH) in Pune, India. The details of the study
are described elsewhere [22]. Briefly, we enrolled children <12 years with known HIV status
who were initiated on first line thrice weekly ATT following a clinically or microbiologically
confirmed TB diagnosis [22]. Of these, 16 participants underwent directly observed therapy
(DOT) either using in-person DOT or using video-assisted DOT to ensure 100% adherence.
No participant reported vomiting or diarrhea on the day of study measurements, and all had
dark brown or black hair.
For this study, semi-intensive PK studies of INH were performed by obtaining plasma sam-
ples at 0, 2, 4, and 6 hours after directly-observed ATT administration at month 2 of treatment.
Plasma concentrations of INH were measured using validated high performance liquid chro-
matography at the National Institute for Research in Tuberculosis (NIRT), Chennai, India
[23]. On the same day of the plasma PK study and also at months 4 and 6, a small thatch of
hair (approximately 20 strands) was cut from the occipital region close to the scalp and from
underneath the top layer of hair as previously described [9,12]. The cut hair was then placed
on a piece of tin foil and taped down at its distal end (side furthest from the scalp) with a thin
label to mark directionality. The specimen was then sealed inside a plastic bag containing a
desiccant pellet, stored at room temperature and shipped to the University of California, San
Francisco, TB Hair Analysis Laboratory for measurement of INH concentrations, as previously
described [22].
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The median and interquartile ranges (IQR) of INH concentrations in hair were calculated.
Similarly, median and IQR of plasma concentrations (maximum concentration, or Cmax) and
exposure (area under the concentration-time curve over 6 hours (AUC0-6)) were calculated.
The linear trapezoidal rule was used to compute AUC0-6; Cmax was determined by visual
inspection of data. Scatterplots were generated to compare log-transformed plasma AUC with
hair concentrations. We examined the associations of plasma AUC at month 2 with hair INH
levels at months 2, 4, and 6. Further, we compared plasma trough concentrations and the hair
INH levels at month 2 and mean hair levels from month 2, 4 and 6 using Spearman rank corre-
lation. The Byramjii-Jeejeebhoy Government Medical College Institutional Ethics Committee
and Johns Hopkins University institutional review boards both approved the study. Parents/
guardians provided written informed consent; participants, when appropriate, provided
assent.
Results
Of 16 children enrolled, the median age was 90 (IQR, 60–105) months; 5 (31%) were between
2 and <5 years of age and 11 (69%) were5 years of age. Nine (56%) were female, 3 (19%)
had HIV co-infection. The median weight was 19.5 (12.35–24.95) kg, and 9 (56%) reported a
history of TB exposure within the last 2 years prior to enrollment; 8 (50%) had pulmonary TB
and 8 (50%) were diagnosed with extrapulmonary TB (EPTB). In-person or video-recorded
directly observed therapy verified 100% adherence to ATT for all 16 children.
The PK parameters from all children are shown in the Table 1. The median and IQR of
INH concentrations in hair for months 2, 4 and 6 were 1.15 (0.54–2.25), 1.86 (0.81–6.32) and
0.90 (0.73–1.09) ng/mg, respectively. The Wilcoxon signed-rank test gave p> 0.95 for month
2 vs 4, p = 0.05 for month 2 vs 6, and p = 0.68 for month 4 vs 6. At 2 months, males tended to
have higher INH hair values.
Table 1. Plasma area-under-the curve (AUC) concentrations and hair concentrations of isoniazid (INH) among children with 100% adherence to
tuberculosis (TB) treatment compared to females (1.64 (1.21–13.2) vs. 0.66 (0.47–1.08), p = 0.05); INH hair levels were lower in older children (corre-
lation = -0.42; p = 0.11) and among children who were heavier (-0.43; p = 0.10).
Age in
months
Sex Weight in kgs HIV Positive? Plasma AUC INH levels, mcg/ml.hrs Hair INH levels at month 2, ng/mg
Child 1 31 M 10 Negative 20.19 39.80
Child 2 113 F 24.9 Negative 23.3775 1.24
Child 3 60 F 12.7 Negative 33.225 1.08
Child 4 26 M 8 Positive 23.7825 13.2
Child 5 102 M 25 Negative 14.9850 1.601
Child 6 115 F 26 Negative 13.7175 0.823
Child 7 31 F 11 Negative 31.2525 19.5
Child 8 68 F 20 Negative 7.9875 0.205
Child 9 60 F 12 Positive 15.72 0.664
Child 10 104 F 19 Negative 22.425 0.466
Child 11 87 M 15 Negative 19.7925 2.858
Child 12 100 F 21 Negative 26.2125 0.103
Child 13 106 M 25 Positive 15.4425 1.635
Child 14 124 M 27 Negative 34.9275 0.365
Child 15 93 M 24 Negative 30.705 1.211
Child 16 78 F 19 Negative 5.5275 0.613
Kgs = kilograms, HIV = Human immunodeficiency virus
https://doi.org/10.1371/journal.pone.0189101.t001
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The median (IQR) AUC was 21.31 (15.21–28.46) mcg/ml.hrs. In contrast to hair levels,
median plasma AUC was similar in females (22.4 (13.7–26.2) mcg/ml.hrs) and males (20.2
(15.4–30.7) mcg/ml.hrs)p = 0.63. The Fig 1 shows the scatterplot of individual hair INH levels
and corresponding plasma AUC measures of INH at month 2. Plasma AUC concentrations
correlated poorly with hair INH concentration at month 2 (correlation coefficient 0.09 (-0.45,
0.62)); correlations were still poor, but improved at month 4 (correlation coefficient 0.21, 95%
confidence interval [CI] (-0.42, 0.84)) and month 6 (correlation coefficient 0.38 (95% CI,
-0.34, 1.00). Among males, the AUC-Hair correlation at month 2 was-0.32 (95% CI, -0.86,
0.56), while among females, it was 0.43 (95% CI, -0.33, 0.85). Plasma trough and peak levels
correlated extremely poorly with hair INH levels with correlation coefficients of -0.060 (95%
CI, -0.56, 0.44) and -0.25 (95%CI, -0.96, 0.47), respectively.
Discussion
This study provides the first information about concurrently measured plasma and hair INH
exposures among children with 100% adherence to ATT, as confirmed via in-person or video-
assessed directly observed therapy. We found that hair levels of INH among highly-adherent
Fig 1. Scatterplot showing 6-hour plasma area-under-the-curve isoniazid concentrations and hair isoniazid concentration (log scale) at month 2
(n = 16).
https://doi.org/10.1371/journal.pone.0189101.g001
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individuals had little correlation with plasma AUC, peak or trough values, with plasma col-
lected on a single occasion using semi-intensive PK sampling.
Suboptimal TB drug exposure increases the risk of TB treatment failure, resistance, recur-
rence and death, especially among children and HIV-infected persons [24–28]. While previous
reports have demonstrated that inadequate INH exposure contributes to poor TB treatment
outcomes in high HIV burden settings [25], limited data are available on target plasma drug
concentrations associated with optimal TB treatment outcomes. A commonly-used ‘target’
Cmax for INH is 3 mcg/mL, but this number is based on typical exposures seen in patients on
TB treatment and not on convincing pharmacokinetic-pharmacodynamic (PK-PD) analyses.
Single plasma levels, like Cmax, may be subject to significant day-to-day variation, with AUC
measures from intensive or semi-intensive PK studies serving as more robust measures of
exposure. However, calculating AUC parameters from even semi-intensive PK studies is an
arduous process requiring a prolonged period of observation and multiple blood draws. More-
over, drug concentrations in hair provide an estimate of longer term exposure than a single
AUC measure, for about one month of drug-taking if the hair is cut to 1 centimeter from the
scalp [19]. Hair is feasible to collect, since it does not require phlebotomy, biohazardous pre-
cautions or a cold-chain, and we have shown high acceptability of hair collection in studies
among Indian children [22](2).
Among children with TB, where drug taking relies on administration by the parent/guard-
ian, and where drug levels can be highly variable due to maturing metabolizing systems, thera-
peutic monitoring of drug levels is likely to be critical for optimizing TB treatment outcomes.
Given the noninvasive nature of hair sampling and the desire to avoid phlebotomy among
young children, hair levels may provide a reasonable alternative to intensive PK sampling to
assess drug exposure during ATT. This study showed poor correlation between hair levels of
INH and plasma PK measures from a single time point. This lack of correlation may reflect the
fact that hair assesses exposure over a much longer time frame than either a single plasma mea-
sure or a 6-hour AUC measure. Also, hair concentrations are influenced by both individual
PK and by adherence over time, whereas single-occasion PK sampling simply demonstrates
individual PK (which may depend on age, pharmacogenetics and other factors). Therefore, the
measures may provide complementary information when assessing exposure among children
on ATT, in the same way that a hemoglobin A1C and short-term blood glucose value may pro-
vide different but complementary information for a patient with diabetes. AUC measurement
was only performed on one occasion and only over 6 hours, compared to the 48-72-hour
inter-dose intervals, so it may not accurately measure the full drug exposure that contributes
to hair levels. Furthermore, similar to data by Eisenhut et al [20], we found gender differences
in hair INH levels, although these did not appear to explain the poor correlation of AUC and
hair levels. Finally, it is possible that INH acetylator status may have influenced both hair and
plasma drug levels as previously reported [20].
A major limitation of this study is that we used a very small subset of children from a larger
study. Of note, as seen in other studies, there were a few hair and plasma levels that were
extremely low. Since adherence was monitored and demonstrated to be 100%, the assumption
is that extremely low levels reflect inadequate drug exposure due to pharmacokinetic variabil-
ity (low absorption, rapid metabolism or clearance).
Pharmacologic measures are increasingly being explored to ensure efficacy of prophylactic
and therapeutic regimens in both clinical studies and routine practice. Our study shows that
hair levels provide information in highly-adherent patients that is distinct from the informa-
tion provided by single-occasion exposure measures. Further study is required to assess the
pharmacodynamic relationship between hair levels of TB drugs and treatment or prevention
Isoniazid levels in hair vs. plasma area-under-the-curve
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outcomes in large cohorts and the incremental value of adding hair to plasma exposure mea-
sures in these studies.
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